Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.
Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
How does the impact of novel therapies vary between different stakeholders?
This is really interesting. For patients, it’s wonderful. We have treatments that are revolutionary, that can cure or dramatically improve the survival outcomes for diseases that really had no good options. The challenges though, they come with significant side effects. For some of them, you actually have to be hospitalized in the intensive care unit when you’re given the drug. That gives you some idea the danger associated with it. Even a successful therapy is a little bit challenging. From a payer perspective or provider perspective, understanding that risk to the patients and the members, understanding that impact of the cost, is a real challenge.
The other piece that I think most people haven’t really thought about is as we think about value in healthcare. Each stakeholder values it differently: employers, patients, family members, physicians, payers. But the biggest challenge is the time horizon that each of those recognize their value. For patients, the time horizon is obviously their life, they're open to measurement on and ongoing fashion. For employers, perhaps the time horizon that’s relevant is the time someone’s an employee. So, amortizing that half a million-dollar dose drug across the employed time makes a little more sense. Theoretically, as an insurance company, you’d value someone just for the time that they’re an insured member, which is a real challenge in these situations, because they need the treatment now, it’s gonna be very expensive now. In a year or two, as you start to break even on that member, of course you wouldn’t with these new therapies but conceptually, they may very well be insured somewhere else, so figuring out how to get that cost fare across the system, it is a real challenge. There’s no good answers yet.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More